Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes... Diabetes Ther (2018) 9:1269–1277 https://doi.org/10.1007/s13300-018-0436-y ORIGINAL RESEARCH Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis . . . . Xia Dai Zu-chun Luo Lu Zhai Wen-piao Zhao Feng Huang Received: April 13, 2018 / Published online: May 9, 2018 The Author(s) 2018 Methods: Electronic databases were carefully ABSTRACT searched for English publications comparing artificial pancreas with its control group. Over- Introduction: Insulin injection is the main all daytime and nighttime glucose parameters treatment in patients with type 1 diabetes mel- were considered as the endpoints. Data were litus (T1DM). Even though continuous glucose evaluated by means of weighted mean differ- monitoring has significantly improved the ences (WMDs) and 95% confidence intervals conditions of these patients, limitations still (CIs) generated by RevMan 5.3 software. exist. To further enhance glucose control in Results: A total number of 354 patients were patients with T1DM, an artificial pancreas has included. Artificial pancreas significantly main- been developed. We aimed to systematically tained a better mean concentration of glucose compare artificial pancreas with its control (WMD - 1.03, 95% CI - 1.32 to - 0.75; P = group during a 24-h basis in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes Therapy Springer Journals

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/artificial-pancreas-as-an-effective-and-safe-alternative-in-patients-06Ne6hXDwv
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Diabetes; Cardiology; Endocrinology
ISSN
1869-6953
eISSN
1869-6961
DOI
10.1007/s13300-018-0436-y
Publisher site
See Article on Publisher Site

Abstract

Diabetes Ther (2018) 9:1269–1277 https://doi.org/10.1007/s13300-018-0436-y ORIGINAL RESEARCH Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis . . . . Xia Dai Zu-chun Luo Lu Zhai Wen-piao Zhao Feng Huang Received: April 13, 2018 / Published online: May 9, 2018 The Author(s) 2018 Methods: Electronic databases were carefully ABSTRACT searched for English publications comparing artificial pancreas with its control group. Over- Introduction: Insulin injection is the main all daytime and nighttime glucose parameters treatment in patients with type 1 diabetes mel- were considered as the endpoints. Data were litus (T1DM). Even though continuous glucose evaluated by means of weighted mean differ- monitoring has significantly improved the ences (WMDs) and 95% confidence intervals conditions of these patients, limitations still (CIs) generated by RevMan 5.3 software. exist. To further enhance glucose control in Results: A total number of 354 patients were patients with T1DM, an artificial pancreas has included. Artificial pancreas significantly main- been developed. We aimed to systematically tained a better mean concentration of glucose compare artificial pancreas with its control (WMD - 1.03, 95% CI - 1.32 to - 0.75; P = group during a 24-h basis in

Journal

Diabetes Therapy – Springer Journals

Published: May 9, 2018

References

  • Genetic epidemiology of type 1 diabetes in the 22 Arab countries
    Zayed, H
  • Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes
    Hurren, KM; O’Neill, JL
  • The health economic value of changes in glycaemic control, weight and rates of hypoglycaemia in type 1 diabetes mellitus
    McEwan, P; Bennett, H; Fellows, J; Priaulx, J; Bergenheim, K
  • Clinical outcomes after 1 year of augmented insulin pump therapy in patients with diabetes in a specialized diabetes center in Medellín, Colombia
    Ramirez-Rincon, A; Hincapie-García, J; Arango, CM
  • “Artificial pancreas” is approved
    Voelker, R
  • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
    Liberati, A; Altman, DG; Tetzlaff, J
  • Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis
    Sterne, JA; Egger, M; Smith, GD
  • Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home
    Blauw, H; Bon, AC; Koops, R; DeVries, JH
  • 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial
    Kropff, J; Favero, S; Place, J
  • Day-and-night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previously reported feasibility study of evening and night at home
    Renard, E; Farret, A; Kropff, J
  • Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study
    Thabit, H; Lubina-Solomon, A; Stadler, M
  • Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas
    Kovatchev, BP; Renard, E; Cobelli, C
  • Outpatient glycemic control with a bionic pancreas in type 1 diabetes
    Russell, SJ; El-Khatib, FH; Sinha, M
  • Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial
    Russell, SJ; Hillard, MA; Balliro, C; Magyar, KL
  • Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia
    Breton, M; Farret, A; Bruttomesso, D
  • Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies
    Hovorka, R; Kumareswaran, K; Harris, J
  • Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes
    Favero, S; Place, J; Kropff, J
  • Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery
    Kovatchev, B; Cheng, P; Anderson, SM